- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 417/00 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group
Patent holdings for IPC class C07D 417/00
Total number of patents in this class: 190
10-year publication summary
|
5
|
8
|
7
|
5
|
6
|
3
|
6
|
1
|
4
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10338 |
8 |
| Bristol-myers Squibb Company | 4789 |
8 |
| Cytokinetics, Inc. | 256 |
7 |
| Merck Sharp & Dohme LLC | 3737 |
6 |
| Janssen Pharmaceutica N.V. | 3213 |
5 |
| Gilead Sciences, Inc. | 2207 |
3 |
| The University of Hong Kong | 825 |
3 |
| Vitro Flat Glass LLC | 503 |
3 |
| LG Chem, Ltd. | 17883 |
2 |
| Allergan, Inc. | 2198 |
2 |
| Shenzhen China Star Optoelectronics Technology Co., Ltd. | 8473 |
2 |
| Life Technologies Corporation | 3392 |
2 |
| Purdue Research Foundation | 3874 |
2 |
| Hutchison MediPharma Enterprises Limited | 11 |
2 |
| Klinikum Darmstadt GmbH | 2 |
2 |
| Ludwig-Maximilians-Universitat Munchen | 336 |
2 |
| Medshine Discovery Inc. | 591 |
2 |
| Purdue Pharma L.P. | 492 |
2 |
| Rigel Pharmaceuticals, Inc. | 509 |
2 |
| The Scripps Research Institute | 1343 |
2 |
| Other owners | 123 |